Pharmafile Logo
Pharmafocus logo
Advanced Search

opdivo

Showing 15 posts of 107 posts found.

BMS shares promising Opdivo/Yervoy data for advanced bladder cancer

December 8, 2016
Research and Development BMS, Yervoy, opdivo

BMS has revealed new efficacy data on the combination of its immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment …

News
flag_of_japan_

Japan to slash Opdivo costs by 50%

November 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Japan, opdivo

Japan’s health ministry has announced it is to slash the price of Bristol-Myers Squibb’s Opdivo by 50% in the country …

News

Blood cancer sufferers to receive early access to BMS’ Opdivo

November 3, 2016
Medical Communications Bristol-Myers Squibb, lyphoma, opdivo

Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through …

News
humacao_exterior

BMS unveils reorganisation plans & boosted profits

October 28, 2016
Business Services, Medical Communications Bristol-Myers Squibb, Yervoy, opdivo

BMS has announced its intention to restructure its operations alongside $3 billion share buyback and quarterly results which exceeded expectations.The …

News
merck_and_co

MSD’s Keytruda given first FDA approval for first line treatment

October 25, 2016
Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo

MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …

News
opdivo_1

FDA accepts another Opdivo indication for priority review

October 24, 2016
Sales and Marketing BMS, Bristol-Myers Squibb, FDA, opdivo

The FDA has accepted a supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb’s Opdivo for treatment of locally advanced unresectable …

News
merck_incweb

MSD’s Keytruda early success ends trial early

October 24, 2016
Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq

MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …

News
opdivo_1_1

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016
Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …

News
roche__tree

Roche’s lung cancer success spells competition for BMS’ Opdivo

October 10, 2016
Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq

Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …

News
merck_and_co

FDA to review MSD’s Keytruda as a first-line lung cancer treatment

September 7, 2016
Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo

The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …

News
roche_close

Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial

September 1, 2016
Research and Development PD-L1, Roche, keytruda, nivolumab, opdivo, phase III, tecentriq

Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …

News
pharmafocus_sept_2016_cover

The September issue of Pharmafocus is now live!

August 31, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo

The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …

News
bms

SMC reverses decision on Opdivo in advanced skin cancer

August 8, 2016
Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer

The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …

News
indiaflag

Opdivo and Keytruda set for India launches by end of year

August 8, 2016
Sales and Marketing India, keytruda, launch, opdivo

Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …

News
opdivo_1

Shock for BMS as Opdivo misses goal in late-stage lung cancer trial

August 5, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo

Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023